Comparison of the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1A1 gene expression profile in lymphocytes from mice, rats, and humans:: Most potent induction in humans

被引:34
作者
Nohara, Keiko [1 ]
Ao, Kana
Miyamoto, Yoshimi
Ito, Tomohiro
Suzuki, Takehiro
Toyoshiba, Hiroyoshi
Tohyama, Chiharu
机构
[1] Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan
[2] Natl Inst Environm Studies, PM2 5 & DEP Res Project, Tsukuba, Ibaraki 3058506, Japan
[3] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Tokyo 1130033, Japan
关键词
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD); lymphocytes; CYP1A1; mRNA; species difference; human;
D O I
10.1016/j.tox.2006.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exerts its toxicity by binding a transcription factor, the aryl hydrocarbon receptor (AhR). C57BL/6 (C57) mice express AhRs that have high affinity for TCDD, and they strongly express target genes and develop severe toxic effects upon TCDD exposure. By contrast, DBA/2 (DBA) mice have a low-affinity form of AhR, weakly express target genes, and are resistant to TCDD. Although humans express low-affinity AhRs and have been assumed to be refractory to TCDD, their sensitivity to TCDD has yet to be determined. In this study we compared the TCDD-induced CYP1A1 gene expression profiles in lymphocytes from humans, C57 mice, DBA mice, and SD rats to obtain data as a basis for estimating human sensitivity to TCDD. Lymphocyte fractions prepared from the blood of individual humans and animals were cultured with TCDD. Their mRNAs for CYP1A1 and housekeeping genes were measured by RT-PCR or real-time PCR with primers designed for regions that are 100% homologous among each of the genes of all species/strains tested to obtain similar PCR efficiency. TCDD-induced CYP1A1 expression peaked at 2 h in DBA mice and SD rats and at 6 h in C57 mice and humans. At the peak times human lymphocytes showed the most potent CYP I A I mRNA induction of the four species/strains tested. These results suggest that human lymphocytes are more sensitive to TCDD than the lymphocytes of mice and rats. Since the AhR-dependent gene expression did not reflect the AhR affinity for TCDD, these results also suggest that AhR-dependent gene expression in lymphocytes is modulated by an as yet unidentified mechanism in addition to the AhR affinity. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:204 / 213
页数:10
相关论文
共 51 条
[1]   AhR, ARNT, and CYP1A1 mRNA quantitation in cultured human embryonic palates exposed to TCDD and comparison with mouse palate in vivo and in culture [J].
Abbott, BD ;
Held, GA ;
Wood, CR ;
Buckalew, AR ;
Brown, JG ;
Schmid, J .
TOXICOLOGICAL SCIENCES, 1999, 47 (01) :62-75
[2]   Dose-response relationship of cytochrome P4501b1 mRNA induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin in livers of C57BL/6J and DBA/2J mice [J].
Abel, J ;
Li, W ;
Dohr, O ;
Vogel, C ;
Donat, S .
ARCHIVES OF TOXICOLOGY, 1996, 70 (08) :510-513
[3]   Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor in activated human B lymphocytes [J].
Allan, LL ;
Sherr, DH .
MOLECULAR PHARMACOLOGY, 2005, 67 (05) :1740-1750
[4]   ERα-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription [J].
Beischlag, TV ;
Perdew, GH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (22) :21607-21611
[5]   A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of ah receptor interacting proteins [J].
Carlson, DB ;
Perdew, GH .
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2002, 16 (06) :317-325
[6]   ERK kinase inhibition stabilizes the axyl hydrocarbon receptor -: Implications for transcriptional activation and protein degradation [J].
Chen, SJ ;
Operaña, T ;
Bonzo, J ;
Nguyen, N ;
Tukey, RH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (06) :4350-4359
[7]   Pharmacological and genetic analysis of 90-kDa heat shock isoprotein-aryl hydrocarbon receptor complexes [J].
Cox, MB ;
Miller, CA .
MOLECULAR PHARMACOLOGY, 2003, 64 (06) :1549-1556
[8]  
DENISON MS, 1986, J BIOL CHEM, V261, P189
[9]  
DOLWICK KM, 1993, MOL PHARMACOL, V44, P911
[10]  
EMA M, 1994, J BIOL CHEM, V269, P27337